A recent nationwide recall of lubricating eye drops is a reminder of how critical product safety is in eye care—and how lapses in manufacturing can directly affect patient health.
In March 2026, California-based manufacturer K.C. Pharmaceuticals voluntarily recalled more than 3 million bottles of over-the-counter artificial tears due to an inability to verify sterility in certain batches.
Why sterility matters
The eye has limited immune defense, making it highly vulnerable to bacteria or fungi introduced through contaminated drops, potentially leading to infections like keratitis or conjunctivitis.
While no infections had been reported as of early April, the potential risk is significant enough to warrant immediate discontinuation of affected products.
Which products were affected?
The recall includes multiple lubricating eye drops sold under various store-brand labels through retailers like CVS, Walgreens, and Kroger.
Patients should check product names and lot numbers against the FDA recall list and return any affected items.
Symptoms to watch for
Redness, discharge, swelling, pain, irritation, or vision changes should prompt immediate evaluation by an eye care professional.
A broader pattern of concern
This recall follows previous FDA findings of contamination risks and manufacturing deficiencies in over-the-counter eye drop production.
A 2023 outbreak linked contaminated drops to a drug-resistant infection causing serious harm, including vision loss and death.
What this means for patients
Staying informed about recalls, purchasing from reputable sources, and consulting professionals when symptoms arise are essential steps for safety.
For clinicians, this underscores the importance of patient education and vigilance regarding over-the-counter ophthalmic products.
Ultimately, safe eye care depends on strict manufacturing standards, regulatory oversight, and informed consumers.